EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

Inhibition of Wnt/β‐catenin pathway overcomes therapeutic resistance to abiraterone in castration‐resistant prostate cancer

Ibrahim M Atawia, Prem P Kushwaha, Shiv Verma, Spencer Lin, Eswar Shankar, Osama Abdel-Gawad, Sanjay Gupta iD

Molecular Carcinogenesis · 2023

DOI: 10.1002/mc.23565 ↗

At a glance

Journal article in Molecular Carcinogenesis, 2023. Written by Ibrahim M Atawia and 6 co-authors. Institution: Department of Urology, Case Western Reserve University, Cleveland, Ohio, USA. Major MEDLINE topics: Prostatic Neoplasms, Castration-Resistant. Cited 14 times so far (Crossref); 51 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: U.S. Department of Defense.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Abiraterone acetate has been clinically approved for the treatment of patients with advanced‐stage prostate cancer. It reduces testosterone production by blocking the enzyme cytochrome P450 17 alpha‐hydroxylase. Despite improved survival outcomes with abiraterone, almost all patients develop therapeutic resistance and disease recurrence, progressing to a more aggressive and lethal phenotype. Bioinformatics analyses predicted activation of canonical Wnt/β‐catenin and involvement of stem cell plasticity in abiraterone‐resistant prostate cancer. Increased expression of androgen receptor (AR) and β‐catenin and their crosstalk causes activation of AR target genes and regulatory networks for which overcoming acquired resistance remains a major challenge. Here we show that co‐treatment with abiraterone and ICG001, a β‐catenin inhibitor, overcomes therapeutic resistance and significantly inhibited markers of stem cell and cellular proliferation in abiraterone‐resistant prostate cancer cells. Importantly, this combined treatment abrogated the association between AR and β‐catenin; diminished SOX9 expression from the complex more prominently in abiraterone‐resistant cells. In addition, combined treatment inhibited tumor growth in an in vivo abiraterone‐resistant xenograft model, blocked stemness, migration, invasion, and colony formation ability of cancer cells. This study opens new therapeutic opportunity for advanced‐stage castration‐resistant prostate cancer patients.

Subjects

MeSH terms (MEDLINE)

Prostatic Neoplasms, Castration-ResistantMaleHumansDrug Resistance, Neoplasmbeta CateninNeoplasm Recurrence, LocalReceptors, AndrogenAndrostenes

Author keywords

androgen deprivation therapyandrogen receptorcancer stem cellscastration resistant prostate cancersignaling pathways

Substances

beta CateninReceptors, AndrogenabirateroneAndrostenes

Authors and institutions

  • Department of Urology, Case Western Reserve University, Cleveland, Ohio, USA.
  • Department of Urology, Menoufia University, Menoufia, Egypt.
  • University Hospitals Cleveland Medical Center, The Urology Institute, Cleveland, Ohio, USA.
  • College of Arts and Sciences, Case Western Reserve University, Cleveland, Ohio, USA.
  • Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio, USA.
  • Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.

ORCID profiles: Sanjay Gupta

Funding

  • U.S. Department of Defense

Cite

APA

Atawia, I. M., Kushwaha, P. P., Verma, S., Lin, S., Shankar, E., Abdel-Gawad, O., & Gupta, S. (2023). Inhibition of Wnt/β‐catenin pathway overcomes therapeutic resistance to abiraterone in castration‐resistant prostate cancer. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23565

Vancouver

Atawia IM, Kushwaha PP, Verma S, Lin S, Shankar E, Abdel-Gawad O, et al. Inhibition of Wnt/β‐catenin pathway overcomes therapeutic resistance to abiraterone in castration‐resistant prostate cancer. Molecular Carcinogenesis. 2023. doi:10.1002/mc.23565

BibTeX
@article{Atawia2023,
  author = {Atawia, Ibrahim M and Kushwaha, Prem P and Verma, Shiv and Lin, Spencer and Shankar, Eswar and Abdel-Gawad, Osama and Gupta, Sanjay},
  title = {Inhibition of Wnt/β‐catenin pathway overcomes therapeutic resistance to abiraterone in castration‐resistant prostate cancer},
  journal = {Molecular Carcinogenesis},
  year = {2023},
  doi = {10.1002/mc.23565}
}
Start for free →